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Reduction of parathyroid hormone with
vitamin D supplementation in blacks: a
randomized controlled trial
Paulette D. Chandler1,2*, Foluso Agboola3, Kimmie Ng2,4, Jamil B. Scott5, Bettina F. Drake6, Gary G. Bennett7,
Andrew T. Chan2,8, Bruce W. Hollis9, Karen M. Emmons2,10, Charles S. Fuchs2,4 and Edward L. Giovannucci2,11,12
Abstract
Background: Response of parathyroid hormone (PTH) to vitamin D supplementation is determined by the baseline
PTH level and change in vitamin D status. Conflicting reports in Blacks exist on the PTH response to vitamin D to
supplementation.
Methods: During 3 winters from 2007 to 2010, 328 healthy Blacks (median age, 51 years) living in Boston, MA were
randomized into a 4-arm, double-blind trial for 3 months of placebo, 1000, 2000, or 4000 IU of vitamin D3. PTH was
measured in 254 participants at baseline and at the end of vitamin D supplementation period.
Results: The differences in PTH between baseline and 3 months were 3.93 pg/mL for those receiving placebo,
-3.37 pg/mL for those receiving 1000 IU/d, -6.76 pg/mL for those receiving 2000 IU/d, and -8.99 pg/mL for those
receiving 4000 IU/d (-2.98 pg/mL for each additional 1000 IU/d of vitamin D3; p < 0.001).
Conclusion: We found a significant decrease in PTH with increasing doses of vitamin D supplementation up to
intakes of 4000 IU/d in Blacks.
Trial registration: Clinical Trials.gov: NCT00585637
Keywords: Vitamin D, Parathyroid hormone, Blacks, Supplementation
Background
Blacks have significantly lower circulating 25-
hydroxyvitamin D [25(OH)D] and higher serum para-
thyroid hormone [PTH] concentrations than Whites
[1, 2]. Observational and intervention studies have
shown that vitamin D deficiency and high serum PTH
are associated with increased risk of skeletal disease [3,
4]. Paradoxically, Blacks have a lower risk of osteopor-
otic fractures partly because of skeletal resistance to
PTH among other factors [5]. Recent studies have
identified an association of high PTH with increased
morbidity and mortality independent of bone disease
[6]. In one study, elevated plasma PTH (>50 pg/mL)
accounted for 20 % of the population-attributable risk
proportion for cardiovascular mortality [7]. A consen-
sus conference on primary hyperparathyroidism sug-
gested that large populations of vitamin D-replete
cohorts are necessary to establish reference intervals
for PTH assays [8]. Furthermore, there has been recent
debate about what constitutes vitamin D deficiency
and sufficiency [9]. The most recent compilation of
data suggest 25(OH)D level of 20 ng/mL (50 nmol/L)
is adequate for the population. However, the 2011 In-
stitute of Medicine (IOM) report concluded that there
is currently only sufficient evidence to provide health
guidelines for skeletal health. For extra skeletal out-
comes, including cancer, cardiovascular disease (CVD),
diabetes mellitus (DM) and autoimmune disorders, the
evidence was inconsistent, inconclusive as to causality
and insufficient to inform nutritional requirements
[10, 11]. The U.S. Preventive Services Task Force
(USPSTF) concluded that the current evidence is in-
sufficient to assess the balance of the benefits and
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harms of screening for vitamin D deficiency in asymp-
tomatic adults [12]. Therefore, more data are needed
to assess the need for vitamin D supplementation for
non-skeletal outcomes and to identify potential thresh-
old effects for non-skeletal outcomes given the current
controversy about the role of PTH [13–16] and vitamin
D in disease pathogenesis. Thus, understanding the
role of vitamin D supplementation on PTH homeosta-
sis is important.
The threshold for vitamin D sufficiency has been de-
fined by some as the lowest serum concentration of
25(OH)D that maximally suppresses PTH secretion [17].
Several studies have reported varying individualized re-
sponses of Vitamin D supplementation on serum level
of PTH [18, 19]. Yet, these studies did not include a suf-
ficient number of Blacks. Therefore, we conducted an
ancillary analysis of the dose–response effect of 3 doses
of vitamin D3 and placebo on PTH levels within a
blinded randomized clinical trial (RCT) to show how
PTH responds to different doses of vitamin D3.
Methods
The parent study was a prospective, randomized, double
blind, placebo-controlled trial of oral vitamin D sup-
plementation in healthy Blacks (Clinical Trials.gov:
NCT00585637). The protocol has been described in
detail previously [20]. The primary goal of the trial was
to examine the effect of daily supplementation of 1000
international units (IU), 2000 IU, and 4000 IU of
vitamin D3 and placebo on plasma 25(OH)D levels.
All participants provided written informed consent.
The project was approved by the Institutional Re-
view Boards of Harvard School of Public Health and
the Dana-Farber Cancer Institute. All procedures
were followed in accordance with the institutional
guidelines.
Recruitment and exclusion criteria
Participants were 30 to 80 years old, understood written
and spoken English and self-identified as Black or
African-American [21–23]. Enrollment during the late
autumn and winter months minimized the influence of
sun exposure on vitamin D levels. A total of 328 individ-
uals living in the Boston area were enrolled into the par-
ent trial (Fig. 1). Exclusion criteria included pregnancy,
renal disease, preexisting parathyroid, thyroid, or cal-
cium metabolism disorders, sarcoidosis, requirement for
calcium channel blockers, type I diabetes, active malig-
nancies (other than non-melanoma skin cancer), and
plan for extended travel to a sunny region during sup-
plementation phase of the study. Primary care physicians
of all enrolled participants were required to provide
documentation that the participant had no prior history
of hypercalcemia.
Randomization and treatment
Participants were randomly assigned to one of four
treatment arms: placebo, 1000 IU (25 mcg)/day, 2000 IU
(50 mcg)/day, or 4000 IU (100 mcg)/day of vitamin D
(as cholecalciferol). Treatment consisted of tablets that,
in addition to placebo or vitamin D, also contained
200 mg of calcium carbonate. The tablets were formu-
lated and manufactured by Pharmavite LLC (Mission
Hill, California). Study medications were started during
early winter (November or December) and were taken
orally once a day for 3 months (completed in February
or March) to minimize any effect of ultraviolet exposure
in New England. Study statisticians generated the ran-
dom allocation sequence. All participants, providers, and
study staff were blinded.
Endpoints and follow up
The primary end point of the study was change in serum
PTH from baseline to the 3-month end of randomized
supplementation. Dietary intake of calcium and vitamin
D was estimated by using a modified Food Frequency
Questionnaire (FFQ) at baseline and 3 months.
Safety and compliance
Participants were followed for toxicity and compliance
every 2 weeks by phone and every 4 weeks in person
during supplementation. Study staff ascertained absence
of symptoms (such as muscle aches, excessive thirst, fre-
quent urination, and nausea). In addition, serum calcium
was measured in all subjects who were taking hydro-
chlorothiazide (HCTZ:84 participants) at 4 to 6 weeks
following study initiation and again at 12 weeks. An add-
itional subset of randomly selected control participants
(44 participants), who were not taking HCTZ, also
underwent calcium assays at 3 months. Serum total cal-
cium was analyzed using standard auto analyzer method-
ology. Any participant with serum calcium >10.5 mg/dL
at the first calcium measurement was immediately discon-
tinued from the study and the primary care physician was
notified. If participants had elevated calcium at month 3
(end of supplementation period), they remained in the
study. Electronic pill-dispenser systems and pill counts
were used to track compliance.
Plasma vitamin D and PTH levels
Blood samples collected at baseline and 3 months were
separated and plasma was stored in liquid nitrogen in
the Dana-Farber Cancer Institute Clinical Research La-
boratory. In this ancillary analysis, PTH was measured
in 254 participants because of lack of stored blood sam-
ples for the others. Although the lower number reduces
our power and statistical precision, the unavailability of
sample is unlikely to cause a bias. All plasma samples were
sent as a single batch to the laboratory of Dr. Bruce Hollis
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(Medical University of South Carolina, Charleston, SC),
where 25(OH)D concentrations were measured using the
Diasorin (DiaSorin, Inc.) radioimmunoassay [24]. The
mean coefficient of variation of 25(OH)D measurements
was 9 %. Samples for PTH assay were sent as a single
batch to Heartland Assays (Ames, Iowa) and measured
using the FDA approved DiaSorin intact PTH immunora-
diometric assay (IRMA). The intra- and inter-assay CVs
for this assay are 2.7 % and 4.3 % respectively. For Heart-
land Assays, the normal range of PTH is 13-54 pg/mL.
For all assays, masked quality control samples were inter-
spersed among the cases and all laboratory personnel were
blinded. Of note, the normal range of PTH reported in la-
boratory manuals is 10-65 pg/mL [25, 26].
Statistical analysis
This trial has a statistical power of 80 % to detect differ-
ences in plasma 25(OH)D level of 5.3 ng/mL between
treatment groups. All statistical analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC with an
intention-to-treat approach. Baseline characteristics of
the study population were compared between supple-
mentation arms using Chi-Square test for categorical
variables and the Kruskal-Wallis test for continuous
Fig. 1 Consolidated standards of reporting trials diagram
Chandler et al. BMC Nutrition  (2015) 1:26 Page 3 of 9
variables. For our primary analysis, we used linear re-
gression with the dose of vitamin D3 (per 1000 IU/day)
as the independent variable and the 3-month change in
PTH as the dependent variable.
We performed a number of a priori secondary ana-
lyses. We used linear regression to evaluate the change
in PTH according to the change in plasma 25(OH)D
levels. Second, we compared the mean change in PTH
between placebo and all three vitamin D treatment
groups combined. Third, we assessed the interaction ef-
fect of HCTZ use on the response of PTH to vitamin D
supplementation. Fourth, we stratified participants based
on baseline 25(OH)D (<20 ng/ml, ≥ 20 ng/ml) and com-
pared PTH change(month 3-month 0), PTH at baseline,
and PTH at 3 months. Finally, to assess whether the ef-
fect of supplementation with vitamin D on the primary
endpoint, 3 month change in PTH, varied according to
baseline 25(OH) D, we tested for interaction between
treatment group and baseline 25 (OH) D levels.
Results
Baseline characteristics among the 328 eligible partici-
pants are shown in Table 1. The overall median age was
51 years with a median BMI of 31 kg/m2. The only sig-
nificant difference in baseline characteristics according
to treatment assignment was that slightly more partici-
pants in the placebo and 1000 IU/day arms had a past
history of cancer than those assigned to 2000 or
4000 IU/day. The compliance with study medication
(measured by electronic pill dispenser system and pill
counts) in the entire cohort was 96.6 % and did not dif-
fer significantly between arms. The 3-month follow-up
plasma measurements were completed in 293 of the 328
participants (89 %). Of the 134/328(41 %) of participants
Table 1 Subject characteristics by supplementation arma,b,g
Characteristic Vitamin D3 Dose Assignment (IU)
PLACEBO 1,000 2,000 4,000 Overall
(n = 81) (n = 81) (n = 83) (n = 83)
Age (y) 50.7 (44.1-58.0)b 51.1 (43.4-60.1) 50.3 (43.5-58.3) 51.3 (44.1-59.7) 51.0 (43.6-59.4)
Sex, No. (%)
Male 27 (33.3) 22 (27.2) 28 (33.7) 29 (34.9) 106 (32.3)
Female 54 (66.7) 59 (72.8) 55 (66.3) 54 (65.1) 222 (67.7)
BMI (kg/m2) 31.2 (26.5-35.9) 30.5 (27.0-37.5) 31.9 (26.2-36.9) 31.4 (27.4-35.7) 31.2 (26.8-36.3)
Biomarkers
PTH (pg/mL) 36.75 (30.40-47.20) 35.40 (28.90-47.25) 36.40 (28.95-47.25) 37.40 (29.40-56.40) 36.9 (29.4-49.0)
25 (OHD) (ng/mL) 15.1 (10.4-23.6) 16.2 (11.0-22.7) 13.9 (9.5-22.3) 15.7 (11.0-23.3) 15.3 (10.4-22.8)
Smoking status, No. (%)
Never 33 (40.7) 36 (44.4) 33 (39.8) 44 (53.0) 146 (44.5)
Past 20 (24.7) 16 (19.8) 27 (32.5) 20 (24.1) 83 (25.3)
Current 28 (34.6) 29 (35.8) 23 (27.7) 19 (22.9) 99 (30.2)
Frequency of exercise, (day/week) 3.0 (0.5-5.0) 3.0 (1.0-5.0) 3.0 (0-5.0) 3.0 (0-5.0) 3.0 (0-5.0)
Dietary vitamin D intake (IU)c 147.3 (71.4-262.8) 162.5 (92.6-295.5) 144.0 (58.0-265.1) 198.1(83.2-306.4) 167.5 (72.3-291.8)
Dietary calcium intake (mg)c 277.0 (171.7-632.3) 422.9 (226.1-795.9) 318.8 (172.7-637.4) 445.9 (198.6-780.4) 356.6 (188.6-693.8)
Regular multivitamin use,d No. (%) 10 (12) 18 (22) 15 (18) 22 (27) 65 (19.8)
Regular vitamin D supplement use,d No. (%) 8 (10) 6 (8) 2 (2) 8 (10) 24 (7.3)
HCTZ use, No. (%) 19 18 12 17 66 (20.1)
Post-menopausal hormone use,e No. (%) 0 0 0 1 (0.5) 1 (0.5)
Regular calcium supplement use,d No. (%) 7 (8.7) 9 (11.1) 7 (8.4) 9(10.8) 32 (9.8)
History of cancer,f No. (%) 6 (7.4) 6 (7.4) 0 3 (3.6) 15 (4.6)
History of hypertension, No. (%) 35 (43.2) 35 (43.2) 36 (43.3) 35 (42.1) 141 (43.0)
aThere were no significant differences in subject characteristics across supplementation arms except where indicated
bMedian; 25th, 75th percentiles in parentheses (all such values) except otherwise stated
cRefers to the intake during the preceding month of selected calcium-rich foods
dDefined as supplement use for 7 days/week during the preceding month
ePercentages were calculated from a total of 222 females
fReported cancers include breast cancer, cervical cancer, uterine cancer, lung cancer, prostate cancer, and sarcoma
gPTH was measured in 254 individuals
Abbreviations: BMI body mass index, PTH parathyroid hormone, 25(OH)D-25 hydroxyvitamin D, HCTZ hydrochlorothiazide)
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using anti-hypertensives, 84/134(63 %) participants were
on a diuretic, HCTZ.
Effect of vitamin D3 supplementation on plasma 25(OH)
D
Among 328 participants, the median 25(OH)D level at
baseline was 15.3 ng/mL. As previously published, base-
line plasma 25(OH)D did not differ significantly between
treatment arms (P = 0.63; Table 2) [27]. Circulating
25(OH)D levels at 3 months differed significantly by the
vitamin D3 supplementation arm, with a median of
14.2, 28.1, 35.5, and 47.3 ng/mL for the placebo,
1000 IU/day, 2000 IU/day, and 4000 IU/day arms, re-
spectively (P < 0.001). [Effect estimate ± SE: 7.7 ±
0.45 ng/mL for each 1000 IU vitamin D3; P-trend,
0.001]. Notably, plasma 25(OH)D decreased at 3 months
among participants treated with placebo (Table 2).
Effect of vitamin D on PTH supplementation
The median [IQR] PTH level at baseline was 36.9 pg/mL
[29.4, 49.0]. At baseline, secondary hyperparathyroidism
(defined as PTH > 60 pg/mL) was present in 40 partici-
pants. Of participants with 25(OH)D < 20 ng/mL, 21.8 %
had PTH ≥ 60 pg/mL compared to 6.8 % of participants
with 25(OH)D ≥ 20 ng/mL. Plasma PTH did not differ
significantly between treatment arms (P >0.05; Table 1).
Plasma PTH declined with vitamin D supplementation.
After 3 months of vitamin D supplementation, partici-
pants with PTH ≥ 60 pg/mL were 4.6 % for 1000 IU/d,
4.7 % for 2000 IU/d, and 3.2 % for 4000 IU/d compared
to 14.5 % for placebo; p for trend = 0.03.
We examined changes in serum PTH according to
vitamin D supplementation in several ways. We deter-
mined the mean PTH for each arm and calculated the
difference between baseline and 3 months follow up.
Serum PTH levels at 3 months differed significantly by
the vitamin D3 supplementation arm, with a mean of
3.9 pg/mL, -3.4 pg/mL, -6.8 pg/mL and -9.0 pg/mL for
the placebo, 1000 IU/day, 2000 IU/day, and 4000 IU/day
arms, respectively (-2.98 pg/mL for each additional
1000 IU/d of vitamin D3 p < 0.001). Using linear regres-
sion with the dose of vitamin D3 (per 1000 IU/day) as
the independent variable and the log10 3-month change
in PTH as the dependent variable, we found a decrease
of -0.07 (0.02) for each additional 1000 IU/d of vitamin
D3 (P < 0.001). (See Additional file 1: Figures S1 and S2)
Comparing all three doses (1000, 2000, 4000 IU/d) ver-
sus placebo, PTH decreased by -10.30 pg/mL (p < 0.001).
Excluding the placebo group, a nonsignificant decrease
in PTH occurred at 3 months (PTH: -1.75 pg/mL 95 %
CI [-3.59-0.08]; p = 0.06, for each additional 1000 IU/d
of vitamin D3) versus change in PTH at 3 months in-
cluding the placebo group (-2.98 pg/mL 95 % CI
[-4.41, -1.54]; p < 0.001).
Relationship between PTH and 25(OH)D
The relationship between PTH and circulating 25(OH)D
was evaluated at baseline and at 3 months. Using a linear
regression at baseline, a 1 ng/mL higher 25(OH)D was
associated with a significant -0.30 pg/mL lower PTH
(p = 0.01). At 3 months, a 1 ng/mL increase in 25(OH)D
resulted in a significant -0.23 pg/mL decrease in PTH
Table 2 Effect of Vitamin D3 Supplementation on PTH (pg/mL) During the Treatment (Baseline to 3 months)a
Vitamin D Dose, IU/d
Parameter, mean (SE) Placebo 1000 2000 4000 3 months Changeb P-Value
n (at baseline) 62 65 64 63
Total PTH, pg/mL −2.98 [-4.41,-1.53] <0.0001
Baseline PTH, mean (SE) 39.40 (14.20) 41.15 (18.02) 42.21 (20.94) 42.96 (16.79)
3 months PTH, mean (SE) 43.27 (18.21) 39.83 (15.56) 36.42 (15.69) 34.18 (12.75)
Difference PTHc, mean (SE) 3.93 (18.93) −3.37 (17.84) −6.76 (14.71) −8.99 (12.36)
25(OH)D, ng/mL
Baseline 25(OH)D, mean(SE) 17.07 (1.03) 17.33 (1.00) 16.12 (0.98) 17.79 (0.98) 7.57 [6.69,8.46] <0.0001
3 months 25(OH)D, mean (SE) 14.23 (0.96) 28.12 (1.11) 35.48 (1.21) 47.30 (1.22)
Difference 25(OH)Dd, mean (SE) −2.58 (0.66) 11.01 (1.22) 19.21 (1.21) 29.79 (1.29)
Calcium, mg/dL
1 month Calcium, mean (SE) 9.54 (0.08) 9.77 (0.13) 9.77 (0.13) 9.81 (0.12)
3 months Calcium, mean (SE) 9.57 (0.09) 9.59 (0.10) 9.59 (0.10) 9.77 (0.07)
aPTH, Parathyroid hormone; mean (SE), mean(Standard Error); IU, international unit. The numbers do not always sum to group totals due to missing information
for some variables
bMonth3 – Month0 change in PTH per 1000 IU/d of vitamin D supplementation, Mean (95 % Confidence Interval). Month3 – Month0 change in 25(OH)D per
1000 IU/d of vitamin D supplementation, Mean (95 % Confidence Interval)
cDifference PTH, Month 3-Month 0 difference in PTH
dDifference 25(OH)D, Month 3- Month 0 difference in 25(OH)D
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(p = 0.0005). These models showed a significant inverse
relationship between 25(OH)D and PTH. No interaction
between baseline 25(OH)D and vitamin D dose effect on
change in PTH was observed (p for interaction = 0.15).
When baseline 25(OH)D was stratified, we observed a sig-
nificant decrease in PTH at 3 months among those with
25(OH)D <20 ng/mL (-3.76 pg/mL 95 % CI [-5.59,-1.92];
p < 0.0001; for each additional 1000 IU/d of vitamin D3)
and a non-significant decrease among those with
25(OH)D ≥ 20 ng/mL (-1.56 pg/mL; 95 % CI [-3.79,0.66];
p = 0.16 for each additional 1000 IU/d of vitamin D3).
Comparing baseline PTH level by 25(OH)D status (defi-
cient versus nondeficient), 25(OH)D < 20 ng/mL: PTH
mean (SD), 42.4 (19.9) pg/mL versus 39.7(14.0) pg/mL for
25(OH)D ≥ 20 ng/mL (p = 0.24). Comparing 3-month
PTH level by 25(OH)D status, 25(OH)D < 20 ng/mL:
PTH mean (SD), 38.1(17.7) pg/mL versus 38.9 (12.0) pg/
mL for 25(OH)D ≥ 20 ng/mL (p = 0.72). No significant
interaction between HCTZ use and change in PTH with
vitamin D supplementation was observed (p for inter-
action = 0.59). Plasma PTH declined in HCTZ and non-
HCTZ users (HCTZ:-4.2 pg/mL 95 % CI [-7.6,-0.85]; p =
0.02; for each additional 1000 IU/d of vitamin D3; non-
HCTZ: -2.51 pg/mL 95 % CI [-4.07,-0.96]; p = 0.002).
Adverse effects
We previously reported the hypercalcemia events [28].
Briefly, after 1 month of the 12-week vitamin D supple-
mentation period, 4 participants taking HCTZ experi-
enced modestly elevated serum calcium levels, ranging
from 10.7 to 11.0 mg/dL. At 3-months, only one HCTZ
participant had elevated calcium (calcium = 11.2 mg/dL).
There were no significant differences in calcium concen-
trations between treatment arms at 1 month (P = 0.14)
and 3 months (P = 0.52).
Discussion
Black Americans have significantly lower 25(OH)D and
higher PTH concentrations than Whites [1, 2]. We eval-
uated the hypothesis that vitamin D supplementation re-
duces PTH in Blacks. PTH has been shown to be a
sensitive biomarker of vitamin D activity in vivo [17]. At
baseline, we found a significant inverse association be-
tween serum 25(OH)D and PTH similar to prior cross-
sectional studies [2]. Vitamin D supplementation led to
an increase in circulating 25(OH)D in this vitamin D-
deficient Black population and a decrease in PTH in a
dose-dependent manner confirming the presence of vita-
min D deficiency based on PTH criteria. Vitamin D defi-
ciency is defined as 25(OH)D less than 20 ng/mL by
IOM, and it provides no formal guidelines regarding
vitamin D screening [29]. The USPTF gives no rec-
ommendation for or against screening and treating
asymptomatic individuals for vitamin D deficiency,
because the evidence regarding the benefits and harms is
insufficient [12].
Vitamin D supplementation had a strong and un-
equivocal effect in lowering PTH when baseline levels
were <20 ng/mL but a weaker and non-significant de-
crease for 25(OH)D > 20 ng/mL. This finding suggests
that a reduction in PTH is clear when 25(OH)D greater
than or equal to 20 ng/mL is attained; a more modest
lowering effect is possible with 25(OH)D levels higher
than 20 ng/mL. A large cross-sectional analysis of
312,962 paired serum PTH and 25-OHD (no informa-
tion provided about race/ethnicity) similarly found sig-
nificant continuing declines in serum PTH levels beyond
20 and 30 ng/ml of 25(OH)D [30], but a larger study
than ours would be required to test this definitively. In
terms of vitamin D dose needed to maximally suppress
PTH, an effect is clear with supplementation of at least
1000 IU/day (e.g., comparing all three doses (1000, 2000,
4000 IU/d) versus placebo, PTH decreased by -10.30 pg/
mL (p < 0.001)). When excluding the placebo group, and
thereby assessing the effect of vitamin D over a range of
1000 to 4000 IU, a nonsignificant decrease in PTH oc-
curred (PTH: -1.75 pg/mL 95 % CI [-3.59-0.08]; p = 0.06,
for each additional 1000 IU/d of vitamin D3). Thus, our
results suggest that intakes higher than 1000 IU/d may
be required to maximally suppress PTH in Blacks. Of
note, in this population, we estimated 1640 IU vitamin
D3/d was needed to raise the plasma 25(OH)D concen-
tration to ≥ 20 ng/mL in ≥ 97.5 % of participants [27].
In agreement with our findings, a systematic review of
clinical trials on the response of parathyroid hormone to
vitamin D supplementation shows that PTH decreases
linearly during vitamin D supplementation for any given
25(OH)D level [31]. Furthermore, the review suggests
that longitudinal vitamin D supplementation studies on
populations with wide range of mobility and age are
needed to further elucidate their modifying effects and
the inter-individual variation in responses of PTH to
vitamin D supplementation [31].
The IOM Report [10, 11] and the Endocrine Society
Clinical Practice Guideline [32] both agree that provid-
ing vitamin D for any reason other than bone health is
not supported by current published literature. The main
way in which the two reports differ is on the upper
threshold for which vitamin D is safe. For the IOM, the
upper threshold is 50 ng/mL but for the Endocrine Soci-
ety it is 100 ng/mL [32]. The basis for their difference is
driven by the interpretation of elevated PTH levels. Con-
troversy remains on how these thresholds were selected
[33]. Neither report recommends vitamin D supplemen-
tation when PTH levels are in the normal range. The
IOM Committee concluded that the evidence that vita-
min D or calcium reduced risk of nonskeletal chronic
disease outcomes is inconsistent, inconclusive, and did
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not meet criteria for establishing cause-and-effect rela-
tionship [10, 11]. Furthermore, the Endocrine Society
states that there is not sufficient evidence to recommend
screening individuals who are not at risk for deficiency
to prescribe vitamin D to attain the noncalcemic benefit
for cardiovascular protection [32].
Few studies have examined the relationship between
vitamin D supplementation and PTH in Blacks. In a
study of 127 postmenopausal Black women randomized
to either placebo or 1000 IU of vitamin D supplementa-
tion with calcium supplement to bring daily calcium in-
take to 1000 mg, serum 25(OH)D increased by 100 % in
supplement users from a baseline of 11.6 ng/mL and
produced a significant decline in PTH at 3 months [34].
In another study of 198 White and African-American
women, participants were randomly assigned to placebo
or daily vitamin D supplementation and were given cal-
cium to maintain total calcium intake of 1000-1200 mg/d.
At 12 months, the investigators concluded that a vitamin
D dose of 400 IU/d increased serum 25(OH)D to greater
than 20 ng/mL in 97.5 % of Whites while 800 to
1600 IU/d was required to reach the same effect in
African Americans [35]. They also found that that
serum PTH reduced significantly in both races over
time but the change was not dose dependent [35].
Reduced bone turnover and reduced risk of osteopor-
otic fractures in Black women compared to White
women [36, 37] have resulted in the suggestion of a
lower cutpoint for normal serum 25(OH)D in Blacks. In
contrast, the Women’s Health Initiative (WHI) nested
case–control study suggested that 25(OH)D greater than
20 ng/mL is associated with increased fractures in Blacks
[38], but the cases had about 50 % more treated diabetes
than the controls (11 % versus 16 %, difference between
groups p = 0.05) and diagnosed diabetes is associated
with greater risk of fractures in Blacks than Whites [39].
Furthermore, they could not test whether the association
between low 25(OH)D levels and fracture was independ-
ent of BMD because only three WHI clinics measured
BMD [38]. Interestingly, this WHI study found no asso-
ciation between PTH and fracture risk in any ethnic
group [38]. Yet, recent studies have implicated low
25(OH)D in increased all-cause and cause-specific mor-
tality in both Blacks and Whites [40–44].
Furthermore, although Blacks have been shown to be
less sensitive to the effects of PTH on bone turnover
[45], serum PTH levels have been shown to be an inde-
pendent risk factor for cardiovascular events, cardiovas-
cular mortality, and all-cause mortality, even in
individuals with PTH within the normal or slightly ele-
vated range [7, 46–49]. A community-based prospective
study of 958 elderly men found that higher plasma levels
of PTH were associated with higher risk for cardiovascu-
lar mortality independently of established cardiovascular
risk factors and factors associated with mineral homeo-
stasis. The results remained significant in participants
with PTH within the normal range. Thus, PTH levels
may portray prognostic information even in the absence
of primary or secondary hyperparathyroidism [7]. In the
health ABC study, elevated PTH (≥70 pg/mL) was asso-
ciated with increased all-cause, CVD, and noncancer,
non-CVD mortality in Black and White community-
dwelling older adults [6].
Strengths of the study include the use of multiple
doses of vitamin D supplementation during winter
months and the use of an all Black cohort. Limitations
of our study include the use of a population with low
calcium intake. Thus, it may not be generalizable to pop-
ulations with higher calcium intake. In addition, we
studied only a short duration of supplementation with 3
doses of vitamin D3 (highest dose 4000 IU/d). Lastly,
this study shows that vitamin D supplementation changes
vitamin D and PTH levels, but it has no outcome measure
as to long term effect on health of changing either vitamin
D or PTH levels and this is a major limitation of the
study design. However, our previous work showed
that vitamin D supplementation in this cohort re-
duced blood pressure [20] without causing hypercal-
cemia even in HCTZ users [28].
Conclusions
This study highlights a dose-dependent decrease in PTH
in Blacks with vitamin D supplementation confirming
correction of low vitamin D, but whether reduction of
PTH should be done or is safe to do is unproven. Identi-
fication of optimal levels of plasma 25(OH)D and PTH
remain to be established.
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